Last reviewed · How we verify

Etomidate Injection

Korea University Anam Hospital · FDA-approved active Small molecule

Etomidate is a non-barbiturate hypnotic agent that enhances GABAergic neurotransmission by acting as a positive allosteric modulator at GABA-A receptors in the central nervous system.

Etomidate is a non-barbiturate hypnotic agent that enhances GABAergic neurotransmission by acting as a positive allosteric modulator at GABA-A receptors in the central nervous system. Used for Induction of general anesthesia, Sedation of intubated patients in intensive care settings.

At a glance

Generic nameEtomidate Injection
SponsorKorea University Anam Hospital
Drug classNon-barbiturate hypnotic; GABA-A receptor positive allosteric modulator
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Etomidate binds to GABA-A receptors and increases the frequency of chloride channel opening, leading to hyperpolarization of neuronal membranes and rapid onset of unconsciousness. It is primarily used as an intravenous induction agent for anesthesia due to its rapid onset, short duration, and minimal effects on cardiovascular and respiratory stability compared to other induction agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: